MicroRNA-200a inhibits cell growth and metastasis by targeting Foxa2 in hepatocellular carcinoma

Shu-ying Chen1*, De-ning Ma2*, Qiu-dan Chen3*, Jing-jun Zhang1, Yue-ru Tian1, Zhi-cheng Wang1, Hao Cai1, Yong Lin1, Hui-chuan Sun4

1. Huashan Hospital, Fudan University, 12 Wulumuqi middle Road, Shanghai 200040, People’s Republic of China
2. Department of Liver Surgery, Fudan University, Shanghai Cancer Center, Cancer Hospital, 270 Dongan Road, Shanghai, People’s Republic of China
3. Department of Central Laboratory, Clinical Laboratory, Jingan District Central Hospital, Fudan University, 259 Xikang Road, Shanghai20040, People’s Republic of China
4. Liver Cancer Institute, Zhongshan Hospital, Fudan University,1609 Xietu Road, Shanghai 200032, People’s Republic of China

*Contributed equally.

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2016.08.30; Accepted: 2016.11.29; Published: 2017.02.25

Abstract

Background: MicroRNAs (miRNAs) are a class of endogenous, small non-coding RNAs which function as essential posttranscriptional modulators of gene expression tightly involved in a wide range of diseases, including the hepatocellular carcinoma (HCC). Here, the present study was designed to investigate the expression levels and cellular roles of miR-200a in HCC.

Methods: Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was used to detect the expression levels of miR-200a in serums and cell lines. Bioinformation analysis, the luciferase reporter assay, qRT-PCR and western blotting were employed to validate Foxa2 as a direct target gene of miR-200a. Cell proliferation, migration and invasion were assessed to identify whether miR-200a could regulate the biological behaviors of HCC cells by targeting Foxa2.

Results: In this study, a low level of miR-200a was observed in patients’ serums and HCC cell lines. Overexpression of miR-200a in HCC cell lines reduced cell proliferation, migration and invasion. In addition, transcription factor forkhead box A2 (Foxa2) was identified as a novel target of miR-200a and downregulated at mRNA and protein levels in miR-200a overexpressed cells. Meanwhile, restoration of Foxa2 significantly reversed the tumor suppressive effects of miR-200a.

Conclusions: These findings indicate that miR-200a regulates the proliferation, migration and invasion of HCC cells by targeting Foxa2, suggesting that miR-200a may function as a potential therapeutic molecular for the diagnosis and treatment of the liver cancer.

Key words: miR-200a, Foxa2, hepatocellular carcinoma, proliferation, migration, invasion.

Introduction

Hepatocellular carcinoma (HCC) is one of the most malignant tumors with high morbidity and mortality, which ranks as the third leading cause of cancer-related death worldwide at present[1-2]. In addition, most HCC patients have a poor prognosis due to late diagnosis and lack of effective treatment[2-3]. Though alpha fetoprotein (AFP) is still the most widely used diagnostic marker, its positive rate is only about 70%[4]. Therefore, it is necessary to identify other specific biomarkers and clarify the molecular mechanism of HCC for the early diagnosis and timely treatment of the disease.

MicroRNAs (miRNAs) are small, noncoding, single-stranded RNAs known to regulate the
expression of genes by binding to the 3′-untranslated region (3′-UTR) of target messenger RNA (mRNA) to participate in the regulation of cell growth, differentiation, apoptosis and metastasis of biological processes\(^5,6\). Many studies have demonstrated that microRNAs have played important roles especially in the evolution and progression of HCC by regulating tumor oncogenes or suppressor genes\(^7-10\).

MicroRNA-200a (miR-200a), a member of the miR-200 family, has been reported to be dysregulated and function as a tumor inhibitor in the pathogenesis of various cancers, such as pancreatic carcinoma\(^11\), renal cell carcinoma\(^12\), nasopharyngeal carcinoma\(^13\), breast cancer\(^14\), ovarian cancer\(^15\) and so on, including HCC. However, the exact role and molecular mechanism of miR-200a in liver cancer have not been elucidated yet.

In the study, we investigated in the expression and functions of miR-200a in the HCC. We found that miR-200a was decreased in HCC. Furthermore, miR-200a suppressed the growth and metastasis of HCC cells by directly forkhead box A2 (Foxa2) and supplement of Foxa2 significantly reversed the tumor suppressive role of miR-200a in HCC cells. Therefore, our study has revealed a novel target for miR-200a and may facilitate a novel treatment of HCC.

**Methods**

**Patients and participants**

Twenty patients with HCC who were treated at the Huashan Hospital affiliated of Fudan University (Shanghai, China) between July 2015 and September 2015 were enrolled into the present study. All the serum samples of HCC patients were collected before and after treatment. We also obtained serum samples from 20 healthy donors who were used as healthy controls. These controls, completely free from any known malignancy or active inflammatory condition, matched with the age, sex and ethnicity of the patients. Blood sample collection obtained informed consent of patients and healthy volunteers. All HCC patients were diagnosed clinically.

**Cell culture**

The human HCC cell lines (HepG2, Huh7, SMMC-7721 and MHCC-97H) and L02 cells were obtained from the Liver Cancer Institute, Zhongshan Hospital, Fudan University (Shanghai, China). The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% Penicillin-Streptomycin (Gibco) and incubated at 37°C in a humidified incubator containing 5% CO\(_2\) following the manufacturer’s instructions.

**Lentiviral miR-200a upregulation assay**

Lentiviruses expressing miR-200a, or negative control miRNA (miR-NC) were commercially obtained from Genechem (Shanghai, China). To transduce hepatocellular carcinoma cell line (Huh7 cell), lentiviruses were added into culture medium overnight with a multiplicity of infection (MOI) of 10. The next day, the fresh DMEM culture medium was replenished. After the cells were continuously cultured for another 4 to 5 days to stabilize the lentivirus transduction, puromycin was used to screen out the stable cell lines. Then, the transduction efficiency was verified by qRT-PCR.

**Luciferase reporter assay**

A luciferase reporter assay was performed in order to detect the direct binding of miR-200a to Foxa2. The entire 3′-UTR of human Foxa2 was cloned into the p-MIR-reporter vector (Ambion, Austin, TX, USA) and confirmed by sequencing to form a wild type luciferase reporter vector (Foxa2 WT 3′-UTR). To verify the binding specificity, the sequences of Foxa2 3′-UTR that bound with the miR-200a were mutated (from AGUGUU to UCACAA), and it was also inserted into p-MIR-reporter vector to generate a mutated luciferase reporter vector (Foxa2 Mut3′-UTR). For the luciferase reporter assays, HEK293 cells were plated in 96-well plates and then transiently cotransfected with luciferase reporter vectors with miR-200a-mimic or control microRNA using Lipofectamine 2000. After transfection for 48h, the relative luciferase activity was detected using a dual luciferase reporter assay system (Promega).

**RNA extraction and quantitative real-time PCR**

RNA was extracted from serum samples using miRNeasy Serum/Plasma kit (Qiagen, Germany) according to the manufacturer instructions. MiRNeasy Mini kit (Qiagen, Germany) was used for the extraction of total RNA from the cells. MiScript SYBR-Green PCR kit (Qiagen, Germany) was performed to detect the mature miR-200a expression in the cells. Expression of cel-miR-39 and RNU6B was used as an endogenous control in serum and cells testing respectively. The mRNA expression of Foxa2 was measured by SYBR-Green qPCR assay (Takara, Dalian, China). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as internal control of Foxa2 mRNA and calculated using the 2\(^{-\Delta\Delta C_{t}}\) formula, and then normalized to the internal control. The primers of miR-200a, cel-miR-39 and RNU6B (hsa-mir-200a, MS00003738; cel-miR-39, MS00019789; hsa-RNU6B, MS00033740) were supplied by Qiagen. PCR of Foxa2 was performed with specific primers:
forward, 5’-CACCACCCACCCACAAA-3’; and reverse, 5’-GGGTAGTGCATCACCTGTTCGT-3’. Primers of GAPDH were as follows: 5’-CGTGGG CCGCCTAGGCCACCA-3’ and 5’-TTGGCTTAGGG TTCAGGGG-3’.

**Protein extraction and western blotting**

All cells were washed with PBS for twice and lysed in IP lysis buffer (Beyotime, China) supplemented with protease and phosphatase inhibitor on ice for 30 min. After that, cell lysates were centrifuged for 30 min (12000 g, 4 °C). Then the protein sample was collected and the protein concentration was measured by using BCA protein concentration assay kit (Beyotime, China). Protein samples were diluted to a certain concentration (5 μg/ul) with the lysis buffer. The proteins (50 μg) were separated by 12% SDS-PAGE and transferred to PVDF membranes (Millipore). After being blocked with skimmed milk, the blots were incubated overnight at 4°C with rabbit anti-foxa2 and anti-β-actin. The membranes were then washed and incubated with goat anti-rabbit secondary antibodies for 60 min, and then developed with BeyoECL Plus kit (Beyotime). The antibodies were purchased from the following sources: Anti-Foxa2 (1:1000, Cell Signaling Technology #3143, USA), anti-β-actin (1:1200, Cell Signaling Technology #8457, USA) and goat anti-rabbit secondary antibodies (1:1200, Santa Cruz, sc2030, USA).

**Cell proliferation assay**

To assess cell proliferation, Huh7 cells were plated in 96-well plates at 5 x 10^3 cells per well in 100μL of culture medium. The cell proliferation index was measured using the Cell Counting Kit-8 (CCK-8; Diojindo Laboratories, Kumamoto, Japan) at 24, 48, 72, 96 and 120 h after transfection. According to the manufacturer’s instructions, each well was treated with 10ul CCK8 solution and incubating for 4 h. The absorbance was measured at 450 nm on Synergy H1 Hybrid Microplate Reader. All experiments were repeated in triplicate.

**Cell migration and invasion assay**

The migration and invasion of cells were tested by using transwell chambers (Corning 3422, USA). In the invasion assay, filters were precoated with Matrigel (BD Biosciences). The cells (5×10^5 cells/200ul) were seeded in the top chamber and the bottom chamber was filled with 600ul DMEM containing 20%FBS. Cells that remained on the bottom surface of the membranes were fixed in methanol for 30 min and stained with 0.5 % crystal violet for 20 min after incubation for 24-48 h. Four random fields were counted for each group.

**Statistical analysis**

All of the western blotting images are representative of at least three independent experiments. Quantitative RT-PCR, the luciferase reporter, the cell proliferation, migration and invasion assays were performed in triplicate. The data are presented as the mean ± SD and all results are analyzed by using Stata 11.0 software. P value less than 0.05 is considered statistically significant.

**Results**

**Clinical features of study participants**

The characteristics of 20 HCC patients and 20 healthy volunteers were presented in Table 1. There was no significant difference in the distribution of age, sex and alanine aminotransferase (ALT) except viral infection and AFP between HCC patients and healthy people. In addition, Table 1 also shows that HCC was more prevalent in males than in females though few cases were studied in the group.

| Pathology characteristics | HCC | Health | P value | χ² |
|---------------------------|-----|--------|---------|----|
| Total                     | 20  | 20     |         |    |
| Gender                    |     |        |         |    |
| Male                      | 15  | 12     | 0.3110  | 1.0256 |
| Female                    | 5   | 8      |         |    |
| Age (years old)           |     |        |         |    |
| <55                       | 12  | 10     | 0.4040  | 0.5250 |
| ≥55                       | 8   | 10     |         |    |
| ALT (U/L)                 |     |        |         |    |
| <40                       | 18  | 20     | 0.1470  | 2.1053 |
| ≥40                       | 2   | 0      |         |    |
| Viral infection (HBV or HCV) | Positive | 11 | 0   | <0.001*** | 15.1724 |
|                           | Negative | 9  | 20    |     |
| AFP serum level (ng/ml)   |     |        |         |    |
| 0-20                      | 10  | 20     | <0.001*** | 13.3330 |
| >20                       | 10  | 0      |         |    |

**MiR-200a is downregulated in HCC serum and cell lines**

We measured the expression of circulating miR-200a in 20 HCC patients before and after resection and 20 healthy subjects using quantitative real-time polymerase chain reaction (qRT-PCR) with the endogenous control (cel-miR-39). The levels of circulating miR-200a expression were markedly decreased in the serum from preoperative patients vs healthy subjects. In addition, the expression level of miR-200a in the serum from the postoperative patients increased significantly compared with the preoperative serum (Fig.1A). We further analyzed whether the preoperative serum level of miR-200a was correlated with clinicopathological factors in 20
patients with HCC (Table 2). The results showed that large tumor sizes of more than 5 cm, TNM stage (III-IV), poor differentiation, the presence of metastasis and recurrences were significantly correlated with low levels of serum miR-200a (P=0.0327, 0.0463, 0.0190, 0.0190 and <0.001, respectively), whereas other clinical factors, such as gender, age, viral infection and liver cirrhosis were not correlated with serum miR-200a levels. The significant clinicopathological factors in univariate analysis were enrolled into a cox model for multivariate analysis, and metastasis and recurrence were identified as independent risk factors for the clinical relevance of miR-200a (Table 3). The above results indicate that miR-200a expression can be detected in the blood samples and may be used as a potential biomarker. To further determine the expression level of miR-200a in cell lines, we also investigated expression of miR-200a in 4 HCC cell lines (HepG2, Huh7, SMMC-7721 and MHCC-97H) and the hepatocyte cell line (L02). The expression of miR-200a in HCC cell lines was significantly downregulated compared with L02 cells (Fig.1B). Among them, Huh7 cell was selected for subsequent investigation. These data strongly suggest that miR-200a may be involved in the occurrence and development of HCC.

Table 2. Relationship between the relative expression of preoperative serum miR-200a and clinicopathological features. *p<0.05, ***p<0.001.

| Pathology characteristics | Case | Preoperative serum miR-200a |
|---------------------------|------|----------------------------|
| Total                     | 20   |                            |
| Gender                    |      |                            |
| Male                      | 15   | 0.350                      | 0.1374 |
| Female                    | 5    | 0.480                      |
| Age (years old)           |      |                            |
| <55                       | 12   | 0.365                      | 0.9378 |
| ≥55                       | 8    | 0.325                      |
| ALT (U/L)                 |      |                            |
| <40                       | 18   | 0.360                      | 0.0122 |
| ≥40                       | 2    | 0.625                      |
| Viral infection (HBV or HCV) |  |                            |
| Positive                  | 11   | 0.370                      | 0.9326 |
| Negative                  | 9    | 0.360                      |
| AFP serum level (ng/ml)   |      |                            |
| 0-20                      | 10   | 0.375                      | 0.7245 |
| >20                       | 10   | 0.265                      |
| Liver cirrhosis           |      |                            |
| Positive                  | 11   | 0.370                      | 0.8355 |
| Negative                  | 9    | 0.360                      |
| Tumor size (cm)           |      |                            |
| <5                        | 14   | 0.380                      | 0.0327*|
| ≥5                        | 6    | 0.140                      |
| TNM stage                 |      |                            |
| 0~II                      | 13   | 0.380                      | 0.0463*|
| III~IV                    | 7    | 0.180                      |
| Differentiation           |      |                            |
| Middle or well            | 13   | 0.380                      | 0.0190*|
| Poor                      | 7    | 0.100                      |
| Metastasis                |      |                            |
| Positive                  | 7    | 0.100                      | 0.0190*|
| Negative                  | 13   | 0.380                      |
| Recurrence                |      |                            |
| Positive                  | 3    | 0.070                      | <0.001***|
| Negative                  | 17   | 0.370                      |

Figure 1. MiR-200a was decreased in HCC serum and cell lines. (A) The levels of circulating miR-200a in serum were detected by qRT-PCR analysis. The relative expression levels of miR-200a in serum were qualified by using a spiked-in cel-miR-39 as an internal control. (B) Relative expression levels of miR-200a in 4 human HCC cell lines (HepG2, Huh7, SMMC-7721 and MHCC-97H), compared to the normal human hepatocyte (L02). Data represent Mean ± SD of 3 replicates. *P<0.05, **P<0.01, ***P<0.001, compared with the negative control (the negative control was preoperative HCC in figure 1A, the negative control was L02 cell in figure 1B).
Overexpression of miR-200a inhibits cell proliferation, migration and invasion in HCC cells

To investigate the effects of miR-200a on tumor biology, stable cell lines expressing miR-200a (Huh7-miR-200a) and its negative control (Huh7-miR-NC) were established by lentiviral transfection, which was validated by qRT-PCR (Fig.2A). Cell proliferation examined with CCK-8 assay demonstrated that overexpression of miR-200a markedly attenuated cell viability of the Huh7 cells as compared with those transfected with the negative control from 48h to 120h (Fig. 2B). The effects of miR-200a on the migration and invasion of HCC cells were analyzed initially in vitro using transwell assays. The results showed that both the migratory and invasive abilities of the HCC cells were suppressed by miR-200a overexpression when compared to the control (Fig. 2C and D). Collectively, the in vitro studies suggest the suppressive effects of miR-200a on tumor cell proliferation, migration and invasion in HCC.

Table 3. Multivariate analysis of clinical factors associated with preoperative serum miR-200a. *P<0.05.

| Factors                        | B     | SE   | Wald | df | P   | EXP(B) | 95% CI        |
|-------------------------------|-------|------|------|----|-----|--------|---------------|
| Tumor size: >5 cm vs ≤5 cm    | -1.643| 0.078| 1.004| 1  | 0.063| 0.193  | 0.518, 0.212  |
| TNM stage: 0-II vs III-IV     | -1.159| 0.115| 0.012| 1  | 0.120| 0.314  | 0.590, 0.223  |
| Differentiation: middle vs poor| 0.715 | 0.018| 2.054| 1  | 0.051| 2.044  | 0.401, 0.035  |
| Metastasis: yes vs no          | -0.536| 0.072| 4.351| 1  | 0.032| 0.029  | 0.506, 0.141  |
| Recurrence: yes vs no          | -2.285| 0.034| 3.008| 1  | 0.028| 0.001  | 0.432, 0.067  |

Figure 2. MiR-200a inhibited proliferation, migration and invasion of HCC cells. (A) Huh7 cells were transfected with miR-200a or negative control lentivirus, and qRT-PCR was performed to determine the expression of miR-200a. (B) Huh7 cells were transfected with miR-200a or negative control lentivirus, and proliferation ability of cells was detected by CCK8 testing kit. (C, D) Transwell assays of Huh7 cells transfected with miR-200a or negative control lentivirus were used to determine the migration and invasion (magnification × 100, Nikon Te2000). Experiments were performed in triplicate. *P<0.05, **P<0.01, ***P<0.001, compared with the negative control (the negative control was Huh7 cells transfected with negative lentivirus in figure 2)
Identification of conserved miR-200a target sites within the 3'-UTR of Foxa2

To further understanding the molecular mechanism of miR-200a in regulating HCC growth and metastasis, we used three publicly available algorithm (Targetscan, miRanda and PicTar), and found that miR-200a was identified as a candidate miRNA that could target Foxa2. The sequence of the predicted miR-200a binding sites and the Foxa2 3'UTR segments containing the miR-200a complementary sequence are shown in Fig. 3A. Luciferase activity assay demonstrated that miR-200a significantly inhibited the wild type (WT) but not the mutant (MUT) 3'-UTR of Foxa2 luciferase activity (Fig. 3B). Furthermore, qRT-PCR and western blotting assay were verified that overexpression of miR-200a markedly suppressed the endogenous mRNA and protein levels of Foxa2 respectively (P<0.05; Fig. 3C and 3D). These data indicate that miR-200a may negatively regulate the transcription of Foxa2 expression by directly targeting its 3'UTR.

Overexpression of Foxa2 reverses the effects of miR-200a on HCC cells

To further confirm Foxa2 was involved in the function of miR-200a, stable cell lines expressing miR-200a (Huh7/miR-200a) were transfected with Foxa2 overexpression plasmid. The expression efficiency of Foxa2 was examined by qRT-PCR and western blotting. The mRNA level and protein level of Foxa2 were both significantly restored in Foxa2 overexpression plasmid-transfected Huh7/miR-200a cells, compared with its negative control (Fig. 4A, 4B). Through analyzing the changes of cell proliferation, migration, and invasion, we found that overexpression of Foxa2 significantly attenuated the miR-200a-mediated tumor suppressive effects (Fig. 4C, D, E). The above results imply that miR-200a serves as a tumor inhibitor mediated by Foxa2.

Discussion

HCC is one of the most common causes of death from cancer. Its 5-year post-surgery survival rate is very low[16]. This poor prognosis is mainly due to the early metastasis and invasion of HCC, which result in an incurable stage most patients’ condition entered [17, 18]. The molecular mechanisms underlying the metastasis and invasion of HCC remain to be explored. Recently, a large number of studies have reported that many miRNAs could participate in the occurrence and development process of liver cancer[19, 20]. Among them, microRNA-200a has been found to be decreased in the liver cancer and play a critical role as tumor suppressor[21-23]. However, the specific mechanisms related with the role of miR-200a in HCC process are still not fully elucidated. In our study, we have for the first time demonstrated that Foxa2 gene was a direct downstream target gene of miR-200a in HCC.

Figure 3. Foxa2 was predicted and confirmed as a potential target of miR-200a in HCC cells. (A) Schematic description of wild-type (WT) and mutant (MUT) 3'-UTR of the human Foxa2. (B) Analysis of luciferase activity results. HEK293 cells were cotransfected with wild-type or mutant 3'-UTR of Foxa2 and miR-200a or the control mimics. The luciferase activities were examined 48h after transfection. (C) Huh7 cells were transfected with miR-200a or the negative control lentivirus. QRT-PCR was performed to observe the mRNA change of Foxa2. (D) Western blotting was analyzed to detect the protein level of Foxa2. *P<0.05, compared with the negative control (the negative control was HEK293 cells transfected with the control mimics in Figure 3B, the negative control was Huh7 cells transfected with negative lentivirus in Figure 3C and 3D).
Figure 4. Overexpression of Foxa2 attenuated the effects of miR-200a. (A) stable cell lines expressing miR-200a (Huh7/miR-200a) were transfected with Foxa2 overexpression plasmid, and the mRNA level of Foxa2 was examined by qRT-PCR. (B) the protein level of Foxa2 was analyzed by western blotting. (C) up-regulation of Foxa2 in Huh7/miR-200a restored partly the ability of cell proliferation by CCK8 assay. (D, E) migration and invasion assays were performed (magnification ×100, Nikon Te2000). The experiments were repeated three times. *P<0.05, **P<0.01, ***P<0.001, compared with the negative control (Huh7 cells transfected with negative lentivirus). #P<0.05, ##P<0.01, ###P<0.001, compared with the negative control (Huh7 cells transfected with miR-200a lentivirus).

To test the hypothesis that miR-200a could play an important role in suppressing the metastasis and invasion of HCC cells, we’ve first analyzed the level of miR-200a expression in the sera and cell lines. It was found that miR-200a was significantly decreased in the preoperative serum of HCC patients compared with the postoperative of the same patients and the healthy people. Furthermore, we investigated the relationship between preoperative serum miR-200a expression of HCC patients and their clinical characteristics. MiR-200a expression level in serum was closely associated with tumor size, tumor stage, differentiation, metastasis and recurrence. Multivariate analysis identified that metastasis and recurrence were independent risk factors for miR-200a. Because liver cancer tissues were difficult to be collected, we did not measure the expression level of miR-200a in tissues. But many literatures have reported that miR-200a is markedly decreased in the HCC[21, 24, 25], consistent with the expected results. It shows that low expression of miR-200a in HCC tissues release less into the peripheral blood, resulting in the low expression of serum miR-200a correspondingly. Moreover, we investigated expression of miR-200a in HCC cell lines and the normal liver cell line (L02). The expression level of miR-200a in 4 kinds of HCC cell lines (HepG2, Huh7, SMMC-7721 and MHCC97H) was lower than the normal liver epithelial cell (L02). In addition, we further researched the functional characteristics of one HCC cell line. Overexpression of miR-200a could suppress HCC cell proliferation, migration and invasion, which is consistent with prior researches [22]. These data suggest that miR-200a may function as a potentially crucial tumor suppressor and the malignancy of liver cancer is restrained by high expression of miR-200a.

It has been well known that miRNAs regulate target gene expression at the posttranscriptional level through both translational inhibition and mRNA degradation. Foxa2 is a member of the fork head transcription factor family which is widely involved in the regulation of cell proliferation and differentiation[26, 27]. Prior studies have showed that Foxa2 may be abnormally expressed in a number of cancers, which sequently lead to the development of tumors[24, 26, 29]. A number of miRNAs have been shown to be able to regulate Foxa2 expression such as miR-1291, miR-29 and miR-124a[27, 30, 31]. But the potential relationship of miR-200a targeting Foxa2 in human hepatocellular carcinoma have not been studied before. In this study, we performed bioinformation software analysis, the luciferase reporter assay, qRT-PCR and western blotting to identify that miR-200a could combine to Foxa2 3’UTR sites and overexpression of miR-200a in Huh7 cell caused a reduction of Foxa2 mRNA and protein. In addition, introducing Foxa2 in miR-200a overexpressed cells could partially reverse miR-200a-mediated tumor suppressive effects. Therefore, it can be inferred that miR-200a may function as a potential therapeutic biomarker for HCC diagnosis.
This study has some potential limitations. In our research, we’ve just employed serums and the only one cell line to identify that miR-200a regulate the growth and metastasis of HCC by targeting the Foxa2 gene. It is felt that we should have confirmed the relationship between the expression status of miR-200a and the development of HCC on clinical tissues, more cell lines and in vivo experiments, which is one limitation of our study. Another limitation is that, though our results showed that miR-200a inhibited cell growth and metastasis through targeting Foxa2 expression, our study did not exclude specific downstream signal pathways that may modulate cell migration and invasion. Thus, in the following, we are going to overcome the attendant limitations of the present study.

Conclusions

Generally speaking, the results of our research demonstrate that miR-200a is frequently down-regulated in HCC patients’ serum and HCC cells, which is likely to be a potential biomarker for diagnosis with an important role as a tumor suppressor in HCC. Decreased expression of miR-200a in HCC cells might lead to aberrant cell proliferation, migration and invasion by regulating the expression of Foxa2 directly, and subsequently contribute to the deterioration of liver cancer. All these results help to further clarifying the mechanisms in the pathogenesis of liver cancer. More importantly, miR-200a might be a novel molecular target for the therapy of HCC.

Abbreviations

HCC: hepatocellular carcinoma; QRT-PCR: quantitative reverse-transcription polymerase chain reaction; Foxa2: forkhead box A2; AFP: alpha fetal protein; miRNAs: microRNAs; 3’-UTR: 3’-untranslated region; mRNA: messenger RNA; DMEM: dulbecco’s modified eagle’s medium; FBS: fetal bovine serum; ALT: alanine aminotransferase

Acknowledgements

We thank Huashan Hospital, Fudan University, Shanghai, China for providing the HCC serum samples and Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China for providing cell lines.

Funding

This work was supported by the National Natural Science Foundation of China (81472224), the National Key Basic Research Program (973 project) from the Ministry of Science and Technology of China (2015CB554005), the Leading Investigator Program of Shanghai municipal government (2016), the National Major Scientific Research Program of China (201526) and the Youth Clinical Medical Technical Talents Training Program of Shanghai (201601).

Ethics approval and consent to participate

All subjects gave informed consent to the study (molecular characterization of liver tumors obtained after curative resection and clinicopathological data associated with the study). The study was approved by the ethics committee of Huashan Hospital, Fudan University.

Competing Interests

The authors declare that they have no competing interests.

References

1. Lamarca A, Mendiola M, Barriuso J. Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. Critical reviews in oncology/hematology. 2016; 105: 65-72.
2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nature reviews Cancer. 2006; 6: 674-87.
3. Yin CQ, Yuan CH, Qu Z, Guan Q, Chen H, Wang FB. Liquid Biopsy of Hepatocellular Carcinoma: Circulating Tumor-Derived Biomarkers. Disease markers. 2016; 2016: 1427949.
4. Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncology reports. 2016; 36: 613-25.
5. Goedeke L, Rotllan N, Canfran-Duque A, Aranda JF, Ramiroe CM, Arzali E, et al. MicroRNA-148A regulates LDL receptor and ARCA1 expression to control circulating lipoprotein levels. Nature medicine. 2015; 21: 1280-9.
6. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215-33.
7. Yao S, Tian C, Ding Y, Ye Q, Gao Y, Yang N, et al. Down-regulation of Kruppel-like factor-4 by microRNA-133a-5p promotes proliferation and metastasis in hepatocellular carcinoma by transforming growth factor-beta1. Oncotarget. 2016.
8. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009; 137: 1055-7.
9. Lin XJ, Chong Y, Guo ZW, Xue C, Yang XJ, Zhang Q, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. The Lancet Oncology. 2015; 16: 804-15.
10. Zhao N, Li S, Wang R, Xiao M, Meng Y, Zeng C, et al. Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells. Biochimica et biophysica acta. 2016; 1859: 933-42.
11. Wu X, Wu G, Wu Z, Yao X, Li G. MiR-200a Suppresses the Proliferation and Metastasis in Pancreatic Ductal Adenocarcinoma through Downregulation of DEK Gene. Translational oncology. 2016; 9: 25-31.
12. Wang X, Jiang F, Song H, Li X, Xian J, Gu X. MicroRNA-200a-3p suppresses tumor proliferation and induces apoptosis by targeting SPAG9 in renal cell carcinoma. Biochemical and biophysical research communications. 2016; 470: 620-6.
13. Shi Z, Hu Z, Chen D, Huang J, Fan J, Zhou S, et al. MicroRNA-20b mediates nasopharyngeal carcinoma cell proliferation through the activation of nuclear factor-kappaB. Molecular medicine reports. 2016; 13: 1732-8.
14. Ming J, Zhou Y, Du J, Fan S, Pan B, Wang Y, et al. Identification of miR-20a as a novel suppressor of connexin 43 in breast cancer cells. Bioscience reports. 2016; 36: 613-25.
15. Zuberti M, Mir R, Das J, Ahmad I, Javid J, Yadav P, et al. Erratum to: Expression of serum mir-20a, miR-20b and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2015; 17: 840.
16. Liu H, Wang S, Ma W, Lu Y. Transforming Growth Factor betal Promotes Migration and Invasion of Human Hepatocellular Carcinoma Cells Via Up-Regulation of Connexin Tissue Growth Factor. Cell biochemistry and biophysics. 2015; 73: 775-81.
17. Jiang YF, Yang ZH, Hu JQ. Recurrence or metastasis of HCC:predictors, early detection and experimental antiangiogenic therapy. World journal of gastroenterology. 2000; 6: 61-5.
18. Li Y, Di C, Li W, Cai W, Tan X, Xu L, et al. Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis. Digestive diseases and sciences. 2016; 61: 2315-27.
19. Han K, Li J, Zhao H, Liang P, Huang X, Zheng L, et al. Identification of the typical miRNAs and target genes in hepatocellular carcinoma. Molecular medicine reports. 2014; 10: 229-35.
20. Afonso MB, Rodrigues PM, Simao AL, Castro RE. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Journal of clinical medicine. 2016; 5.
21. Feng J, Wang J, Chen M, Chen G, Wu Z, Ying L, et al. miR-200a suppresses cell growth and migration by targeting MAXC1 and predicts prognosis in hepatocellular carcinoma. Oncology reports. 2015; 33: 713-20.
22. Zhong C, Li MY, Chen ZY, Cheng HK, Hu ML, Ruan YL, et al. MicroRNA-200a inhibits epithelial-mesenchymal transition in human hepatocellular carcinoma cell line. International journal of clinical and experimental pathology. 2015; 8: 9922-31.
23. Hung CS, Liu HH, Liu JJ, Yeh CT, Chang TC, Wu CH, et al. MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Annals of surgical oncology. 2013; 20 Suppl 3: S360-8.
24. Yang X, Wang J, Qu S, Zhang H, Ruan B, Gao Y, et al. MicroRNA-200a suppresses metastatic potential of side population cells in human hepatocellular carcinoma by decreasing ZEB2. Oncotarget. 2015; 6: 7918-29.
25. Dhayat SA, Mardin WA, Kohler G, Bahde R, Vowinkel T, Wolters H, et al. The microRNA-200 family--a potential diagnostic marker in hepatocellular carcinoma? Journal of surgical oncology. 2014; 110: 430-8.
26. Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer research. 2016; 70: 2115-25.
27. Tu MJ, Pan YZ, Qiu JX, Kim EJ, Yu AM. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget. 2016.
28. Hamilton G, Hochmair M, Rath B, Klameth L, Zeillinger R. Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype. Cell adhesion & migration. 2016; 1:8.
29. Li CM, Gocheva V, Oudin MJ, Bhutkar A, Wang SY, Date SR, et al. Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes & development. 2015; 29: 1850-62.
30. Kurtz CL, Peck BC, Fannin EE, Beyer C, Miao J, Landstreet SR, et al. MicroRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes. 2014; 63: 3141-8.
31. Jing G, Westwell-Roper C, Chen J, Xu G, Verchere CB, Shalev A. Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through miR-124a and FoxA2. The Journal of biological chemistry. 2014; 289: 11807-15.